Alliances
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
SomaLogic and Illumina have come together to propel innovation in Proteomics. This partnership represents the rapidly growing high throughput sector of the proteomics market
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical’s jointly prepared treatment for Angelman syndrome have been provided a green single by DSMB recently.
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
It’s been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
Pfizer and BioNTech are developing a vaccine for the prevention of shingles while Moderna is in a Phase I study of an mRNA vaccine for the Epstein-Barr Virus.
DNA Script announced it secured a $200 million Series C financing, bringing the total amount raised by the biotech company to $315 million since its founding in 2014.
Biogen exercised an option to pick up an exclusive global license for a drug to treat spinal muscular atrophy from Ionis. The compound, BIIB115, is an antisense oligonucleotide.
PRESS RELEASES